The guideline recommends the establishment of a Data Monitoring Committee (DMC) to oversee the trial's progress, particularly in terms of safety. In cancer trials, the DMC plays a crucial role in ensuring patient safety, especially when evaluating new therapies that may have significant adverse effects. The DMC can recommend modifications or even early termination of the trial based on interim data.
